
Debiopharm
- Home
- Companies
- Debiopharm
- Products
- Eloxatin - Oxaliplatin for Cancer ...

Eloxatin - Oxaliplatin for Cancer Treatment
FromDebiopharm
Oxaliplatin is a diaminocyclohexane (DACH) platin. It is the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®, which has dramatically changed the prognosis of colorectal cancer. In 1996, prior to the introduction of oxaliplatin, the standard of care for colorectal cancer was 5-fluorouracil (5-FU). Combination of oxaliplatin with 5-FU and leucovorin (FOLFOX) allowed to more than double the survival of patients with metastatic disease. In 2000’s approval of oxaliplatin in adjuvant settings has significantly increased the number of patients cured. It is a worldwide standard treatment in metastatic colorectal cancer.
Most popular related searches
colorectal cancer
iv infusion
clinical development
pancreas cancer
liver cancer
cancer treatment
pancreas
infusion solution
pancreatic colorectal
patient survival
Indications
- Metastatic colorectal cancer
- Adjuvant setting in colorectal cancer
- Pancreatic cancer in USA and in Japan
- Liver cancer in China
Product Characteristics
- 3 dosages: 50mg – 100mg – 200mg
- IV infusion
- Freeze-dried and solution formulations
Debiopharm Value Added
- Identification of the first clinical indication (mCRC)
- Clinical development leading to the first file submission registration in France
- Optimization of the efficacy-safety profile